
Glaxosmithkline Pharmaceutical share price
NSE: GLAXO · Healthcare
₹2,651.70 -0.78%
Closing price data, updated 17 Nov 2026. 52-week range: -15.0% from high, +27.0% above low.
Price₹2,651.70
Market cap₹44,921 Cr
P/E39.2
P/B23.88
ROE49.1%
ROCE55.4%
Debt / equity0.01
Dividend yield0.00%
EPS₹67.68
Book value₹111.04
Operating margin32.8%
Dipscan score59 / 100
Share: WhatsAppX / TwitterTelegram
Glaxosmithkline Pharmaceutical shareholding pattern
As of Sep 2026: Promoters 75.00%, FIIs 4.75%, DIIs 8.48%, Government 0.00%, Public 9.65%, Others 2.12%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FIIs | 4.75% | 4.79% | 4.62% | 4.64% | 4.80% | 4.89% |
| DIIs | 8.48% | 7.80% | 7.68% | 7.70% | 7.75% | 7.70% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 9.65% | 10.21% | 10.35% | 10.36% | 10.34% | 10.32% |
| Others | 2.12% | 2.20% | 2.35% | 2.30% | 2.11% | 2.09% |
| No. of Shareholders | 119,337 | 126,087 | 121,763 | 122,460 | 122,904 | 123,629 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -0.78% | +5.03% | +4.44% | -0.60% | +9.72% | +7.08% |
Growth
| Sales growth, 3 years | +5.7% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +19.3% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | – |
| Latest quarter profit vs last year | – |
Strengths and weaknesses
Strengths
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
- Company has been maintaining a healthy dividend payout of 94.6%
Weaknesses
- Stock is trading at 23.9 times its book value
- The company has delivered a poor sales growth of 5.49% over past five years.
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Glaxosmithkline Pharmaceutical?
Glaxosmithkline Pharmaceutical (GLAXO) last closed at ₹2,651.70 (-0.78% on the day).
What is the market cap of Glaxosmithkline Pharmaceutical?
About ₹44,921 Cr.
What is the P/E ratio of Glaxosmithkline Pharmaceutical?
The price-to-earnings ratio is 39.2, and return on equity is 49.1%.
Figures are calculated from company results and exchange prices and are for information only.